1316 In addition to the high prevalence, there are several major challenges that must be considered as risk factors for the outcome of hyperammonemic individuals in the Middle East
The FDA has not approved any oral form, whether pill, tablet, capsule, sublingual drop, or dissolving tablet
Some studies have shown potential benefits in lowering blood pressure and alleviating inflammatory processes associated with heart diseases
Calcium channel blockers: an update
In order to elucidate this multifaceted clinical syndrome, complex pre-clinical models approximating the human reality are needed
Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG , Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA